PubMed · 1995 · 17 citations · 23 references
MedicineOncologyPathologyCellular PathologyMonoclonal AntibodiesOncogenesImmunohistochemistryPleural MalignanciesPleural TumorsTumor AntigensTumor HistopathologyTumor MarkersC-myc RegulationFos OncogenesImmunohistochemistry In Pleural NeoplasmsImmunohistochemistry In Tumor DiagnosisMalignant Pleural Mesothelioma ImagingMonoclonal Antibodies In CancerMyc OncogenesPleural Tumor Immunohistochemistry
We studied immunoreactivity for c-fos protein and c-myc protein in malignant mesothelioma (36 cases) and non-neoplastic pleural mesothelium (45 cases) using the murine monoclonal antibodies 14E10 and 6E10. All malignant mesotheliomas and cases with non-neoplastic mesothelium exhibited not only nuclear but also cytoplasmic immunoreactivity for c-fos and c-myc protein in the majority of mesothelial cells. There was no statistically significant difference between the various mesothelioma subtypes or between neoplastic and non-neoplastic mesothelium for c-fos protein immunoreactivity (p > 0.05). There was statistically significant difference between neoplastic and non-neoplastic mesothelium for c-myc protein immunoreactivity (p < 0.01). We conclude that immunoreactivity for c-fos and c-myc protein is present in both non-neoplastic and neoplastic mesothelium, but that a higher proportion of neoplastic mesothelial cells are immunoreactive for c-myc protein when compared with non-neoplastic mesothelium.
23
The c-fos protein interacts with c-JunAP-1 to stimulate transcription of AP-1 responsive genes
Robert Chiu, William J. Boyle, Jennifer Meek et al. · Cell · 1988 · 1.4K citations · Full text
Expression of Cellular Oncogenes in Human Malignancies
Dennis J. Slamon, Jean B. deKernion, Inder M. Verma et al. · Science · 1984 · 833 citations
Medicine, Cancer Biology, Oncology +13